Prostate cancer, PI3K, PTEN and prognosis

Helen M. Wise, Miguel Hermida Ayala, Nicholas R Leslie*

*Corresponding author for this work

Research output: Contribution to journalArticle

130 Citations (Scopus)
220 Downloads (Pure)


Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most common driving events in prostate cancer development. The observed mechanisms of PTEN loss are diverse, but both homozygous and heterozygous genomic deletions including PTEN are frequent, and often accompanied by loss of detectable protein as assessed by immunohistochemistry (IHC). The occurrence of PTEN loss is highest in aggressive metastatic disease and this has driven the development of PTEN as a prognostic biomarker, either alone or in combination with other factors, to distinguish indolent tumours from those likely to progress. Here, we discuss these factors and the consequences of PTEN loss, in the context of its role as a lipid phosphatase, as well as current efforts to use available inhibitors of specific components of the PI3K/PTEN/TOR signalling network in prostate cancer treatment.

Original languageEnglish
Pages (from-to)197-210
Number of pages14
JournalClinical Science
Issue number3
Early online date5 Jan 2017
Publication statusPublished - Feb 2017


  • AKT
  • Phosphatase
  • Phosphoinositide 3-kinase (PI3K)
  • Prostate cancer

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Prostate cancer, PI3K, PTEN and prognosis'. Together they form a unique fingerprint.

Cite this